Abstract 2136P
Background
Prostate cancer (PC) patients face treatment-related sequelae that affect their health and quality of life. The PCSC Program was created in 2013 and is located in the Vancouver Prostate Centre’s urology clinic. It is a clinical, educational, and research-based program that addresses challenges experienced by PC patients from the time of diagnosis onward. The program consists of 8 “modules” listed in the table.
Methods
We describe the operational details of the PCSC Program and its metrics.
Results
A Medical Director and Program Manager set the mission, oversee the day-to-day operations, and hire and manage the allied health clinicians and support staff. Office/clinic space is rotated during the week to accommodate a sexual health RN (1.4 FTE), 2 pelvic floor physiotherapists, a nurse practitioner, a registered dietitian, a clinical exercise physiologist (all 0.2 FTE), and a clinical counsellor (0.4 FTE). As of 05/2023, 3351 pts have registered for this no-cost program (Table). In 4/2020, the real-time group education sessions and clinic appointments transitioned from in-person to a hybrid with virtual options enabling the participation of patients from throughout British Columbia.
Table: 2136P
Attendance at PCSC modules for 3351 registrants from 2013 to May 2023
Modules | Attendees, n | Group education*, n (# sessions) | Clinic appointments, n (# appointments) |
Introduction to PC and primary treatment options | 945 | 955 (159) | not applicable |
Managing sexual function and intimacy | 1745 | 844 (122) | 1519 (6109) |
Management of side effects of ADT | 443 | 376 (25) | 212 (313) |
Pelvic floor physiotherapy for incontinence | 1304 | 910 (97) | 594 (2382) |
Counselling | 444 | not applicable | 444 (1629) |
Metastatic disease management | 85 | 87 (30) | not applicable |
Nutrition | 742 | 195 (31) | 361 (593) |
Exercise | 826 | 455 (70) | 674 (2167) |
*Some attendees attended the group education sessions more than once.
Conclusions
The need for PC supportive care is well recognized but may be challenging to offer when the services are fragmented and time-consuming for clinicians or staff to arrange. All modules offered by the PCSC Program can be accessed with one registration. It is convenient for patients because it is housed in one location, which also facilitates communication across disciplines. We attribute the success of our program to this model and our team approach to the individual patient’s needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prostate Cancer Supportive Care Program.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2237P - Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial
Presenter: Nicolas Huyghe
Session: Poster session 07
2238P - Tebentafusp reprograms immunosuppressive tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
Presenter: Josep M. Piulats
Session: Poster session 07
2239P - Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
Presenter: Elia Segui Solis
Session: Poster session 07
2240P - Novel genetic markers associated with immune checkpoint inhibitor induced immune-related adverse events
Presenter: Ik Shin Chin
Session: Poster session 07
2241P - A novel 89Zr-anti-PD-1 immuno-PET-CT may predict response to PD-1 inhibitors and improve response assessment in a lung cancer murine model receiving immunotherapy
Presenter: Ander Puyalto
Session: Poster session 07
2242P - Engineering immune-cell targeting nanoparticles for precise delivery of loaded-cargo and enhanced immunotherapy efficacy
Presenter: Na Kyeong Lee
Session: Poster session 07
2243P - Immune-modulating magnetic nanoparticles to enhance the immune response for the treatment of breast cancer metastasis and recurrence
Presenter: Jaesung Lim
Session: Poster session 07
2244P - Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models
Presenter: Vincenzo Quagliariello
Session: Poster session 07
2245P - Graphene oxide: A promising platform for delivery of cancer immunotherapy
Presenter: Sorayut Chattrakarn
Session: Poster session 07
2246P - Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
Presenter: Elia Segui Solis
Session: Poster session 07